Aptamer Group has secured a new contract worth up to £617,000 with a top-five global pharmaceutical company, marking the third project between the two firms. The deal strengthens an existing partnership built on Aptamer’s Optimer® platform, which develops synthetic binders for drug discovery and diagnostics.
The new agreement covers the development of Optimers for three drug targets and technical support for ELISA assay development, enabling the client to validate new drug candidates and potentially use the tools in clinical testing. Aptamer will retain intellectual property rights for all Optimers developed under the deal, opening future licensing opportunities as the technology proves commercially viable.
Dr Arron Tolley, Chief Executive Officer of Aptamer Group, said the new partnership highlights growing industry recognition of the company’s platform and commercial potential. “This contract represents significant commercial validation and increasing traction of our Optimer® technology platform. The decision by a top five pharmaceutical partner to commission this large-scale, multi-target programme follows the successful completion of a proof-of-concept project where we demonstrated the superior performance of our Optimers compared to traditional antibodies and our ability to successfully deliver binders, to support our customers with their critical projects.
This means the Group now has a signed contract value of £1.75 million for this financial year, with eight months of the financial year remaining. As such, we are well-positioned to build on last year’s performance and deliver sustained revenue growth. We continue to build a robust foundation of repeat business with leading pharmaceutical partners, converting our commercial pipeline into long-term value for shareholders.”
Aptamer has reported signed contract values totalling £1.75 million so far this financial year, up 46% from the same period last year. Management expects this growing pipeline to support continued revenue growth into FY26, following a strong performance in FY25.
